Proxeon
Proteomics - sample preparation, nano LC, uHPLC, HPLC, nano ES, data interpretation - Thermo Scientific.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor investor investor | €0.0 | round | |
N/A | Acquisition | ||
| Total Funding | 000k | ||
| EUR | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
Proxeon is a leading provider of diagnostic solutions focused on enhancing global health and safety. The company operates in the healthcare and life sciences market, offering advanced testing technologies that aid in the detection and prevention of diseases. Proxeon's primary clients include hospitals, medical laboratories, and research institutions. The business model revolves around the development, production, and distribution of diagnostic tests and related services. Revenue is generated through the sale of diagnostic kits, equipment, and ongoing service contracts. Proxeon is committed to innovation and works closely with regulatory authorities to ensure the availability of reliable and effective diagnostic solutions. The company has played a significant role in addressing public health challenges, such as the COVID-19 pandemic, by producing millions of diagnostic tests.
Keywords: diagnostic solutions, global health, safety, testing technologies, healthcare, life sciences, hospitals, medical laboratories, research institutions, COVID-19.